Quick Answer
Inhibrx Biosciences, Inc. reported Total Revenue of $1.30 million for fiscal year 2025.
Inhibrx Biosciences, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $1.30M | +550.0% |
| 2024 | $200.0K | -88.9% |
| 2023 | $1.80M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | — | -100.0% |
| June 30, 2025 | $1.30M | +1200.0% | — |
| September 30, 2024 | $0.00 | -100.0% | -100.0% |
| June 30, 2024 | $100.0K | +233.3% | -16.0% |
| September 30, 2023 | $119.0K | — | +296.7% |
| June 30, 2023 | $30.0K | — | — |
- Inhibrx Biosciences, Inc. showed an increase of +550.0% in Total Revenue compared to the prior fiscal year.
- Over the 2023–2025 period, Inhibrx Biosciences, Inc.’s total revenue has declined by 27.8% (from $1.80 million to $1.30 million).
- The most recent figure is from Inhibrx Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: